Trials / Completed
CompletedNCT04771676
Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites
A Phase II Study of Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of effectiveness, safety and local immune activation of Oncolytic Viruses H101 in patients with refractory malignant ascites.
Detailed description
This study is to evaluate the effectiveness of local immune activation, and safety in patients with refractory malignant ascites after Intraperitoneal injection of oncolytic Viruses H101.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oncorine (H101) | A modified human recombinant type 5 adenovirus with genetic modifications. |
Timeline
- Start date
- 2021-03-05
- Primary completion
- 2023-01-31
- Completion
- 2023-01-31
- First posted
- 2021-02-25
- Last updated
- 2023-01-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04771676. Inclusion in this directory is not an endorsement.